
By Dr. Rose Jalang’o, Head, National Vaccines & Immunization Program, Ministry of Health
When I started my career as a medical officer in Thika, a town about an hour away from Nairobi, we would often see a steady surge of children with high fevers, breathing difficulties and general lethargy at our hospital facility. When examined, these children would be breathing faster than normal, have very low oxygen levels on the pulse oximeter and look unusually tired.
Most of these children could not go home and needed to be admitted to our wards for oxygen therapy, antibiotics and close supervision. Some unfortunately did not make it back home at all.
We were losing too many children to pneumonia; A preventable disease caused by the pneumococcal bacteria and whose complications can cause ear and sinus infections, meningitis or life-threatening bloodstream infections.
When Kenya introduced the pneumococcal conjugate vaccine (PCV) in 2011, there was an immediate impact in the pediatric wards. Fewer children were being admitted with the most severe forms of pneumonia, meningitis, and bloodstream infections. At the household level, fewer families were facing the emotional and financial strain of prolonged hospital stays and fewer children were succumbing to pneumonia.
Looking back at the Kenya PCV introduction in 2011, Christine, a nurse at Kilifi County hospital, witnessed the decline firsthand: “It was like a miracle. The outpatient clinic no longer had crowded queues with mothers coming in with children with pneumonia.”
Few public health interventions have delivered results as dramatic as Kenya’s pneumococcal vaccination program. Evidence from the KEMRI-Wellcome Trust Research Program’s long-term surveillance in Kilifi shows that after the introduction of the pneumococcal conjugate vaccine (PCV10) in 2011, hospital admissions for severe pneumonia among children under five declined by 27%, while radiologically confirmed pneumonia fell by nearly half. Even more remarkable, vaccine-type invasive pneumococcal disease among young children declined by more than 90%. These gains were not limited to vaccinated children alone. The vaccine also reduced disease transmission within communities, providing protection to infants too young to be vaccinated and others who had missed vaccination. These numbers represent far more than statistics. They reflect fewer children admitted to hospital wards, fewer families facing devastating medical costs, and more children surviving and thriving.
As I lead Kenya’s immunization program, I am proud of how far we have come since my days as a medical officer. Vaccines quietly protect children long before they ever need a hospital bed. They mean fewer children struggling to breathe from pneumonia, fewer parents facing the fear of losing a child, and fewer families carrying the burden of preventable illness. Instead, I see more children celebrating birthdays, attending school, playing with their friends, and growing up healthy. That is the true power of vaccines.
Today, more than 8 of every 10 Kenyan children receive all three PCV doses. This achievement demonstrates the strength of Kenya’s immunization system. It also proves that vaccines are not only a shield for individuals but also a powerful tool for reducing disease burden across society.
For example, the PCV vaccine is an important tool to fight antimicrobial resistance (AMR), which occurs when bacteria stop responding to the medicines used to treat them. Evidence shows that deaths linked to drug-resistant infections are rising faster in sub-Saharan Africa than anywhere else in the world. Kenya’s National Action Plan on AMR recognizes immunization as an important measure of control because every case of pneumonia prevented by PCV can mean one less course of antibiotics, which reduces the opportunity for resistant strains to spread.
The decline in invasive pneumococcal disease, reflects Kenya’s sustained investment in health and is testament to the diligent monitoring, smart procurement decisions and strength of the national immunization program. Throughout the country, national and county leaders worked together to introduce PCV and track its impact and sustain coverage over the years. We have also invested in a robust health workforce at national and sub national level who help deliver these vaccines to our communities. These investments from the Ministry of Health and partners ensure that health care workers are trained and supervised; mother child clinics are kept stocked and community health workers are sensitized so that they can support demand creation efforts.
While scientific innovation makes life saving vaccines possible, sustainable financing makes their impact lasting. Securing and sustaining long-term resources is a vital part of the equation, ensuring that every child can continue to benefit from lifesaving protection year after year.
As one of the first countries to introduce the PCV in the region, Kenya has already shown that it can make smart funding decisions. In 2022, the Kenya National Advisory Technical Advisory Group (KENITAG), an expert group advising the Kenyan Ministry of Health on vaccines, reviewed the available PCV vaccines and specifically looking at their safety, cost and reliability of supply resulting in a recommendation of a PCV vaccine product that offered equal protection at a lower price. That decision saved an incredible US$1.05 per dose, close to US$4.9 million in vaccine costs. Savings like these can pay for training community health workers, repairing and expanding cold chain equipment, and widening the network of trusted local voices who counter misinformation.
The ability to make strategic procurement choices will become even more important under Gavi’s new 6.0 funding model, where governments will receive an advance, multi-year vaccine budget and have much greater control over their allocation. Currently, Kenya Invests USD 50 million for vaccine procurement as a commitment to domestic financing, and the investment will continue to grow as we graduate out of donor support.
Kenya’s experience in making smart funding decisions offers a practical lesson for other countries facing a similar burden of pneumococcal disease. As: Gavi support evolves and countries assume greater responsibility for financing their immunisation programs, the question many governments are asking is clear: how can we continue funding PCVs while facing competing health priorities and constrained budgets?
Kenya’s experience offers an important lesson for countries that have a high burden of pneumococcal disease. Smart, evidence-based funding decisions can help countries not only introduce but sustain life saving pneumococcal vaccines and protect hard won public health gains in the face of declining funding and budget constraints.
When I think back to my years in Thika, I often think about the children we treated for pneumonia, the ones who fought for every breath as their parents watched anxiously at their bedsides. My greatest joy today however comes from thinking about the children we never had to treat, who never developed severe pneumonia and who were never admitted to hospital or put on oxygen because they were protected from pneumococcal disease. That is the true power of vaccines. Giving children a shot at simply being healthy children who can learn, play, grow and dream.
By continuing to invest in immunization, we are investing in healthier children, stronger communities, and a brighter future for generations to come.”
Vaccination Protects Life!

